Literature DB >> 17274052

Prognostic factors for Korean patients with anaplastic thyroid carcinoma.

Tae Yong Kim1, Kyung Won Kim, Tae Sik Jung, Jung Min Kim, Sun Wook Kim, Ki-Wook Chung, Eun Young Kim, Gyungyub Gong, Young Lyun Oh, Soo Youn Cho, Ka Hee Yi, Won Bae Kim, Do Joon Park, Jae Hoon Chung, Bo Youn Cho, Young Kee Shong.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC), although rare, is one of the most aggressive human cancers, and patients with ATC have extremely poor prognoses despite various therapeutic measures. We wished to determine the prognostic factors of survival and effect of treatment on survival rate in patients with ATC.
METHODS: We retrospectively reviewed the medical records of the 121 patients (41 men and 80 women) diagnosed with ATC from January 1995 to June 2004 at 5 major referral centers in Korea.
RESULTS: Mean patient age at diagnosis was 64 +/- 11 years (range, 17-84 years). Of the 121 patients, 11 (9%) had intrathyroidal tumors, 69 (57%) had extrathyroidal tumors or lymph node involvement, 29 (24%) had distant metastases, and 12 had no data about staging (9%). The mean tumor diameter was 5.5 +/- 2.5 cm (range, 0.5-17.0 cm). At a median follow-up of 41 months (range, 26-122 months), 8 patients were alive. Median survival time was 5.1 months. The disease-specific survival rates were 42% at 6 months, 16% at 12 months, and 9% at 24 months. Sixteen patients (13%) received only supportive care, 25 (21%) received surgery alone, 20 (16%) received radiation treatment or chemotherapy without surgery, and 60 (50%) received surgery plus radiation treatment or chemotherapy. Multivariate analysis showed that age less than 60 years, tumor size less than 7 cm, and lesser extent of disease were independent predictors of lower disease-specific mortality.
CONCLUSIONS: Long-term survival is possible for ATC patients less than 60 years old and with small localized tumors. Although aggressive multimodal therapy, including surgery, radiation treatment, and chemotherapy, was not significantly associated with improved survival, we advocate aggressive multimodal therapy in selected ATC patients with good prognostic factors.

Entities:  

Mesh:

Year:  2007        PMID: 17274052     DOI: 10.1002/hed.20578

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  22 in total

1.  Dyspnea as a prognostic factor in anaplastic thyroid carcinoma.

Authors:  Lauren Tashima; Ron Mitzner; Saima Durvesh; David Goldenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-20       Impact factor: 2.503

2.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

3.  Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.

Authors:  Iwao Sugitani; Akira Miyauchi; Kiminori Sugino; Takahiro Okamoto; Akira Yoshida; Shinichi Suzuki
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 4.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

5.  Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

Authors:  Sarika N Rao; Mark Zafereo; Ramona Dadu; Naifa L Busaidy; Kenneth Hess; Gilbert J Cote; Michelle D Williams; William N William; Vlad Sandulache; Neil Gross; G Brandon Gunn; Charles Lu; Renata Ferrarotto; Stephen Y Lai; Maria E Cabanillas
Journal:  Thyroid       Date:  2017-02-16       Impact factor: 6.568

6.  Marginal treatment benefit in anaplastic thyroid cancer.

Authors:  Megan R Haymart; Mousumi Banerjee; Huiying Yin; Francis Worden; Jennifer J Griggs
Journal:  Cancer       Date:  2013-07-09       Impact factor: 6.860

Review 7.  Management of anaplastic thyroid cancer.

Authors:  Xavier M Keutgen; Samira M Sadowski; Electron Kebebew
Journal:  Gland Surg       Date:  2015-02

8.  18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.

Authors:  Thomas Poisson; Désirée Deandreis; Sophie Leboulleux; François Bidault; Guillaume Bonniaud; Sylvain Baillot; Anne Aupérin; Abir Al Ghuzlan; Jean-Paul Travagli; Jean Lumbroso; Eric Baudin; Martin Schlumberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-06       Impact factor: 9.236

Review 9.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

10.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.